NCT06889493 2025-12-17
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Phase 1 Recruiting
Clinical Trials
3 trialsNCT05262556 2025-08-07
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06041516 2025-07-11
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting